Skip to main content

Table 1 Baseline characteristics for cases with incident type 2 diabetes mellitus and referents

From: Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study

 

Total population

n

Cases

n

Referents

p-value

Time to T2DM diagnosis, years

157

5.5 ± 2.7

-

-

-

Age, years

157

50.5 ± 8.1

277

50.2 ± 8.3

matched

Sex, male (%)

157

56.7

277

56.7

matched

Family history of T2DM, n (%)

154

48 (31.4)

269

44 (16.4)

< 0.001

Non, Ex, Daily smoking, n (%)

156

56 (35.9), 56 (35.9), 44 (28.2)

272

112 (41.2) 105 (38.6) 55 (20.2)

0.163

Sedentary, Moderate, Active, n (%)

157

23 (14.6), 116 (73.9), 18 (11.5)

277

48 (17.3), 190 (68.6), 39 (14.1)

0.507

Hypertension*, n (%)

157

104 (66.2)

277

39 (32.1)

< 0.001

Antihypertensive medication, n (%)

157

41 (26.1)

277

16 (5.8)

< 0.001

Systolic blood pressure, mmHg

157

139.2 ± 18.3

276

127.5 ± 16.8

< 0.001

Diastolic blood pressure, mmHg

157

87.0 ± 12.5

276

79.7 ± 10.4

< 0.001

Fasting plasma glucose, mmol/L

157

5.9 ± 0.8

277

5.2 ± 0.7

< 0.001

2-h plasma glucose, mmol/L

157

8.2 ± 2.1

277

6.5 ± 1.7

< 0.001

BMI, kg/m2

156

29.5 ± 4.2

277

25.3 ± 3.6

< 0.001

Total cholesterol, mmol/L

157

6.0 ± 1.0

277

5.7 ± 1.0

< 0.001

HDL, mmol/L

157

1.1 ± 0.3

277

1.3 ± 0.3

0.002

Triglycerides, mmol/L

157

1.7 (1.3 - 2.5)

277

1.1 (0.9 - 1.6)

< 0.001

tPA, ng/mL

156

11.0 (8.7 - 13.7)

276

7.7 (5.6 - 10.5)

< 0.001

PAI-1, ng/mL

157

35.0 (23.9 - 46.1)

276

21.2 (14.6 - 31.3)

< 0.001

tPA/PAI-1 complex, ng/mL

155

7.9 (5.2 - 0.4)

277

3.8 (2.5 - 5.8)

< 0.001

VWF, %

156

142.9 (119.1 - 178.9)

276

124.0 (96.0 - 159.6)

< 0.001

  1. Values are mean ± SD for continuous, and percent for non-continuous variables. Median and interquartile range presented for variables not displaying normal distribution.
  2. BMI: body mass index; CRP: C-reative protein; T2DM: type 2 diabetes mellitus; tPA: tissue plasminogen activator; PAI-1: plasminogen activator inhibitor-1; VWF: von Willebrand factor; SD: standard deviation.